Table 4 Application of DNMTi and HDACi to OC treatment

DNMTi

 SGI-110

1. Drug sensitizer used in combination with cisplatin

[156]

2. Enhances the immune recognition of tumor cells by regulating MHC class I and immunomodulatory molecules in EOC cells, and is superior to AZA or DAC

[157]

 5-Aza-2’-deoxycytidine (5-AZA-CdR)

Upregulate endogenous retrovirus (ERV) with G9Ai, synergistically induce antitumor

[158]

 5-Azacytidine (5AZA-C)

Induced the recruitment of activated (IFNγ⁺) CD4⁺T cells, CD8⁺ T cells and NK cells combining with α-difluoromethylornithine (DFMO)

[159]

HDACi

 Entinostat (class I HDACi)

Synergistic effect with cisplatin in HGSOC

[160]

 Vorinostat

Inhibit tumor growth and prolong survival via targeting CD146

[161]

 Panobinostat

1. Synergistic effect with carboplatin in EOC

[162]

2. Reduce homologous recombination (HR) cyclin E-overexpression, as a means of enhancing PARPi activity

[163]

 Thailandepsins

Inhibit cell viability and induce apoptosis

[164]

 Suberoylanilide hydroxamic acid (SAHA)

Combined olaparib induced apoptosis and pH2AX expression more strongly to a greater extent than either drug alone

[165]